Application of a stochastic modeling to evaluate tuberculosis onset in patients treated with tumor necrosis factor inhibitors

Elena Agliari,Lorenzo Asti,Adriano Barra,Rossana Scrivo,Guido Valesini,Robert S. Wallis

DOI: https://doi.org/10.1371/journal.pone.0055017

2013-04-19

Abstract:In this manuscript we apply stochastic modeling to investigate the risk of reactivation of latent mycobacterial infections in patients undergoing treatment with tumor necrosis factor inhibitors. First, we review the perspective proposed by one of the authors in a previous work and which consists in predicting the occurrence of reactivation of latent tuberculosis infection or newly acquired tuberculosis during treatment; this is based on variational procedures on a simple set of parameters (e.g. rate of reactivation of a latent infection). Then, we develop a full analytical study of this approach through a Markov chain analysis and we find an exact solution for the temporal evolution of the number of cases of tuberculosis infection (re)activation. The analytical solution is compared with Monte Carlo simulations and with experimental data, showing overall excellent agreement. The generality of this theoretical framework allows to investigate also the case of non-tuberculous mycobacteria infections; in particular, we show that reactivation in that context plays a minor role. This may suggest that, while the screening for tuberculous is necessary prior to initiating biologics, when considering non-tuberculous mycobacteria only a watchful monitoring during the treatment is recommended. The framework outlined in this paper is quite general and could be extremely promising in further researches on drug-related adverse events.

Medical Physics

What problem does this paper attempt to address?

The problem this paper attempts to address is the assessment of the reactivation risk of Mycobacterium tuberculosis (TB) and non-tuberculous mycobacteria (NTM) infections during the treatment with tumor necrosis factor inhibitors (TNF inhibitors). Specifically, the authors applied stochastic modeling methods to study the risk of latent TB infection reactivation and the occurrence of new TB infections in patients treated with TNF inhibitors. Additionally, the paper explores the situation of NTM infections, particularly whether these infections are also affected by TNF inhibitors.

### Main Issues:
1. **Mycobacterium tuberculosis (TB) Infection**:
- **Latent Infection Reactivation**: Assess the risk of latent TB infection reactivation during TNF inhibitor treatment.
- **New Infections**: Evaluate the possibility of new TB infections during the treatment process.

2. **Non-tuberculous Mycobacteria (NTM) Infection**:
- **Latent Infection Reactivation**: Investigate the reactivation risk of NTM infections during TNF inhibitor treatment.
- **New Infections**: Assess the possibility of new NTM infections during the treatment process.

### Research Methods:
- **Stochastic Modeling**: Establish a mathematical model using Markov chain analysis to describe the transition probabilities between different states.
- **Parameter Estimation**: Estimate key parameters in the model, such as the probability of latent infection reactivation (R) and the probability of new infections (N), through numerical simulations and experimental data.
- **Analytical Solution**: Derive the analytical solution of the model to predict the number of infection cases over time.

### Main Findings:
- **Mycobacterium tuberculosis (TB) Infection**:
- The probability of latent TB infection reactivation is significantly higher in patients treated with Infliximab compared to those treated with Etanercept.
- Trend of infection cases over time: The Infliximab treatment group shows exponential growth, while the Etanercept treatment group shows linear growth.

- **Non-tuberculous Mycobacteria (NTM) Infection**:
- The reactivation of NTM infections plays a minor role during TNF inhibitor treatment.
- Trend of infection cases over time: Shows quadratic growth, consistent with the assumption of a minor role of latent infection reactivation.

### Conclusion:
- **Clinical Significance**:
- Screening for TB infection before using TNF inhibitors is necessary.
- For NTM infections, close monitoring during treatment is recommended rather than strict screening.

- **Theoretical Significance**:
- Stochastic modeling methods have potential in assessing drug-related adverse events and can provide useful tools for future related research.